Exploring the Link Between SSRIs and Sexual Dysfunction
Part 2 of our 3-part investigation into the dangers of SSRIs for adolescents
FAIR in Medicine is dedicated to supporting the scientific method, viewpoint diversity, and rigorous inquiry in the search for objective truth. We believe that intolerance is the enemy of free and open inquiry and respectful scientific debate. FAIR's advocacy for the rights of biological women and girls in sports and other protected spaces is premised on the need for objective scientific truth, but we also recognize the need to advocate for rigorous scientific inquiry beyond issues relating to gender. As part of this effort, FAIR has launched a three-part series to examine the benefits, risks, and impact of antidepressants. In the future, we will explore other areas in which scientific debate and inquiry have been stifled by intolerance to the detriment of doctors and patients.
Part 2: Are We Chemically Reshaping Adolescent Identity?
In Part 1 of our investigation, we exposed how the widespread prescribing of Selective Serotonin Reuptake Inhibitors (SSRIs) to adolescents rests on questionable science, a debunked chemical imbalance theory, and a flawed FDA approval process. But we're now confronting an even more disturbing question: Are we chemically reshaping adolescent identity through mass SSRI prescription, and might there be a relationship between these drugs and the unprecedented surge in gender dysphoria?
The correlation is striking and demands investigation: As SSRI prescriptions for teenagers have skyrocketed over the past decade, so too have gender dysphoria diagnoses. Yet this potential connection remains virtually unexplored scientifically. We're playing Russian roulette with adolescent development. If SSRIs can permanently alter sexual function in fully developed adults, what profound and irreversible changes might they be inflicting on teenagers whose sexual and gender identities are still forming? During this critical window when young people are just beginning to understand their bodies and sense of self, we may be chemically derailing normal development with consequences that could last a lifetime.
The Gender Dysphoria Crisis
The past decade has witnessed an unprecedented explosion in gender dysphoria diagnoses among adolescents. Most troubling is the emergence of what researchers term Rapid Onset Gender Dysphoria (ROGD)—a phenomenon disproportionately affecting adolescent girls. Unlike traditional gender dysphoria with childhood onset, these cases typically emerge suddenly during or after puberty, often within peer groups and following immersion in social media.
The work of Dr. Lisa Littman demonstrates an unprecedented 4,000% increase in adolescent girls seeking gender treatment in the past decade. Some clinics report shifts from predominantly male patients with childhood-onset dysphoria to 70-80% adolescent females with no previous history of gender distress. This demographic shift alone should prompt scientific investigation.
What's particularly concerning is how this surge maps onto another trend: CDC data shows that by age 17, nearly 20% of girls have been prescribed antidepressants—almost twice the rate for boys. We cannot ignore that females are significantly more likely than males to be prescribed SSRIs during adolescence. Simultaneously, we've witnessed the cultural pathologizing of adolescent development, with normal female bodily experiences and emotional responses increasingly medicalized.
Is it merely coincidental that the demographic most heavily medicated with serotonin-altering drugs is the same demographic experiencing unprecedented rates of gender dysphoria? This is the question every researcher and practitioner should be asking but isn't.
The Critical Developmental Window at Risk
Adolescence represents an irreplaceable period of biological, psychological, and social transformation. The brain undergoes massive restructuring—the prefrontal cortex develops while neural connections are extensively pruned—a process continuing into the mid-twenties. Simultaneously, sex hormones trigger profound physical changes that fundamentally alter how teenagers experience themselves as sexual beings.
Identity formation happens through a complex interplay of biology and social relationships. Adolescents gauge who they are through emotional responses to others, creating neurological pathways that will define sexual and gender identity for decades. Today's adolescents navigate this natural confusion while encountering ideologies suggesting that discomfort with one's developing body indicates a cross-sex identity—providing a framework for interpreting normal developmental distress.
When we introduce SSRIs during this critical period, we're potentially interfering with the neurobiological processes that guide identity formation. These drugs manipulate one of the most critical neurotransmitter systems involved in sexual functioning, social bonding, and bodily awareness—precisely the domains undergoing dramatic development during adolescence. How might these neurochemical changes, intersecting with cultural narratives that pathologize normal development, be reshaping fundamental aspects of identity?
Dangerous Manipulation of a System We Barely Understand
Pharmaceutical companies once claimed that depression results from a "chemical imbalance"—specifically, low serotonin levels. This theory, which fueled the mass prescription of SSRIs, has now been thoroughly debunked. We're manipulating a neurotransmitter system in developing adolescents based on a theory we now know is false. If SSRIs don't actually correct a chemical imbalance, what are they doing to the developing brain?
Serotonin—one of the brain's most complex neurotransmitters—plays a critical role in sexual and gender development. It interacts bidirectionally with sex hormones like testosterone and estrogen, influencing everything from sexual desire to gender-typical behaviors. Different serotonin receptors serve distinct functions: 5-HT1A receptors enhance sexual desire, while 5-HT2 receptors regulate both sexual arousal and sense of body ownership.
When flooded with artificially elevated serotonin, the brain compensates through down-regulation—reducing both serotonin production and receptor sensitivity. This compensatory response disrupts the delicate balance of receptor subtypes crucial for sexual function, body perception, and gender-typical behaviors.
Animal studies reveal the alarming developmental consequences. Rodents exposed to serotonin-altering drugs during development display permanently altered sexual behavior patterns. Male rats exhibit feminized behaviors, including reduced aggression and altered mating. Female rats show masculinized behaviors and disrupted reproductive cycles. Most crucially, these changes persist into adulthood—long after the chemical intervention stops—suggesting permanent rewiring of neural circuits related to sexual development.
Perhaps the most concerning effect is "emotional blunting," reported by 40-60% of SSRI users. This dampening of both positive and negative emotions creates a state of detachment from bodily sensations and emotional experiences. Neuroimaging studies show decreased activity in brain regions associated with empathy. The ability to emotionally connect with peers shapes gender identity, romantic relationships, and social role development—all potentially compromised by medication that dampens these essential emotional responses.This impairment in emotional connection carries profound implications for adolescent development, as empathy forms the foundation for healthy relationships, moral reasoning, and social identity formation.How can adolescents develop authentic identities when the emotions that help define the self are chemically suppressed?
Emotional numbness, bodily detachment, and identity confusion are both common SSRI side effects and frequently cited experiences among adolescents questioning their gender. The parallels are striking! Is this merely coincidence, or are we witnessing pharmaceutical side effects being misinterpreted through cultural frameworks that suggest such disconnection indicates gender incongruence?
What happens when adolescents experiencing medication-induced detachment encounter online narratives suggesting these feelings mean they were "born in the wrong body"? The resulting confusion—pharmaceutical in origin but cultural in interpretation—may be driving life-altering decisions based on iatrogenic symptoms rather than authentic identity.
Post-SSRI Sexual Dysfunction: The Ethical Crisis We're Ignoring
The most alarming and well-documented effect of SSRIs is Post-SSRI Sexual Dysfunction (PSSD)—a condition characterized by reduced sexual sensation, decreased libido, and diminished capacity for emotional attachment that persists long after medication discontinuation. This isn't a rare side effect; it's a devastating reality for countless patients, recognized in medical literature and by regulatory agencies. The ethical implications are staggering: We're giving drugs known to cause potentially permanent sexual dysfunction to adolescents who haven't yet developed their sexual identity. If we consider it unethical to permanently alter a child's sexual function through other interventions, why would pharmaceutical interference be any different?
Teenagers prescribed SSRIs during the critical window of sexual development may never experience normal sexuality. With no "before" to compare to, these young people have no way to recognize that their lack of sexual desire or romantic attraction is medication-induced rather than innate. Their sexual identity forms within an artificially altered neurochemical environment, potentially resulting in a lifetime of dysfunction they don't even recognize as abnormal.
In my clinical practice, I regularly encounter young adults in their twenties who report a complete absence of sexual desire. Many identify as asexual and exhibit gender confusion, believing this represents their natural state. Almost invariably, these individuals were prescribed SSRIs during early adolescence—precisely when sexual identity typically develops. Those who do discontinue these medications sometimes report experiencing sexual desire and romantic attraction for the first time in their mid-twenties, having lost a decade of normal sexual development.
The implications for identity development are profound. Sexuality represents a core aspect of human identity, influencing not just romantic relationships but our sense of self, emotional connection, and place in the world. By chemically suppressing this fundamental aspect of human experience during its formative period, we may be unwittingly reshaping not just sexual function, but identity itself.
The question isn't whether SSRIs affect sexual development—we know they do. The question is whether we can ethically justify giving these drugs to young people whose sexual identities are still forming, knowing we may be permanently altering this fundamental aspect of their humanity without their fully informed consent. No adolescent can meaningfully consent to potential lifelong sexual dysfunction when they haven't yet experienced what healthy sexuality feels like. Not to mention, many providers may fail to inform adolescents or their parents of these potential side effects and unintended consequences.
The Ethical Imperative: Stop the Experiment Now
The evidence demands immediate action. We're conducting an unprecedented chemical experiment on developing adolescent brains with potentially lifelong consequences. When interventions carry significant risk of permanent harm to children who cannot provide informed consent, the burden of proof must lie with those promoting the intervention—not those questioning it.
Given what we now know about SSRI-induced sexual dysfunction, emotional blunting, and identity disruption, continuing to prescribe these drugs to adolescents represents an ethical failure. We wouldn't accept such risks with other medical interventions for non-life-threatening conditions in children. Why do we make an exception for psychiatric medications?
The time has come for a moratorium on SSRI prescriptions for children and adolescents. Simultaneously, we must require research that focuses on:
Understanding the long-term effects of early SSRI exposure on identity development
Investigating the potential link between SSRI use and gender dysphoria
Developing protocols to safely taper adolescents off these medications
Our children deserve nothing less than our courage to confront this inconvenient truth: In our well-intentioned effort to help struggling adolescents, we may have fundamentally altered who they were meant to become. The greatest act of care now is to stop, acknowledge what we've done, and commit to understanding the damage before another generation pays the price.
In Part 3 of our investigation, we'll explore practical alternatives to psychiatric medication for supporting adolescent mental health.
If your teen is currently taking an SSRI, do not discontinue it without medical supervision. Withdrawal effects can be serious and require careful management.
We welcome you to share your thoughts on this piece in the comments below. Click here to view our comment section moderation policy.
The opinions expressed here do not necessarily reflect those of the Foundation Against Intolerance & Racism or its employees.
In keeping with our mission to promote a common culture of fairness, understanding, and humanity, we are committed to including a diversity of voices and encouraging compassionate and good-faith discourse.
We are actively seeking other perspectives on this topic and others. If you’d like to join the conversation, please send drafts to submissions@fairforall.org.
Excellent points. In addition to the hazards you cite, the reflexive prescription of such drugs to teens medicalizes their distress, communicating that they lack the inner self-healing resources to overcome difficulties with the aid of supportive professionals and others. Drugs deprive them of the growth in self-esteem and confidence in knowing that they surmounted their challenges, which is how personal growth occurs in all of us. If, on the other hand, their angst reflects a medical disorder, only a doctor can cure it and they must depend on the doctor and drugs. But as a long-practicing psychiatrist I have another gripe: the incompetence of swarms of psychotherapists who refer clients to MDs for drugs because of their own clinical ineffectiveness. For sure the assumptions of psychiatry must be challenged across the board, but so too must the evidently inadequate training of many therapists, who form a pipeline along with PCPs into the psychiatric prescription racket.
This is a hugely important article. Having taken ssri s for 20 years, i conform that all this is true. Luckily, i took them as an adult, because the effects would have been even worse had i taken them as a child. Their effects persist long after you stop them, yet most doctors refuse to ackowledge this. When i told my psychiatrist this, she claimed that was impossible and mocked me. Yet, clearly, i am not the only one to have noticed this. Thank you for this important work.